Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion
Sebastian P. Gnosa, Laia Puig Blasco, Krzysztof B. Piotrowski, Marie L. Freiberg, Simonas Savickas, Daniel H. Madsen, Ulrich auf dem Keller, Pauliina Kronqvist, Marie Kveiborg
Sebastian P. Gnosa, Laia Puig Blasco, Krzysztof B. Piotrowski, Marie L. Freiberg, Simonas Savickas, Daniel H. Madsen, Ulrich auf dem Keller, Pauliina Kronqvist, Marie Kveiborg
View: Text | PDF
Research Article Oncology

ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion

  • Text
  • PDF
Abstract

Macrophages in the tumor microenvironment have a substantial impact on tumor progression. Depending on the signaling environment in the tumor, macrophages can either support or constrain tumor progression. It is therefore of therapeutic interest to identify the tumor-derived factors that control macrophage education. With this aim, we correlated the expression of A Disintegrin and Metalloproteinase (ADAM) proteases, which are key mediators of cell-cell signaling, to the expression of protumorigenic macrophage markers in human cancer cohorts. We identified ADAM17, a sheddase upregulated in many cancer types, as a protein of interest. Depletion of ADAM17 in cancer cell lines reduced the expression of several protumorigenic markers in neighboring macrophages in vitro as well as in mouse models. Moreover, ADAM17–/– educated macrophages demonstrated a reduced ability to induce cancer cell invasion. Using mass spectrometry–based proteomics and ELISA, we identified heparin-binding EGF (HB-EGF) and amphiregulin, shed by ADAM17 in the cancer cells, as the implicated molecular mediators of macrophage education. Additionally, RNA-Seq and ELISA experiments revealed that ADAM17-dependent HB-EGF ligand release induced the expression and secretion of CXCL chemokines in macrophages, which in turn stimulated cancer cell invasion. In conclusion, we provide evidence that ADAM17 mediates a paracrine EGFR-ligand-chemokine feedback loop, whereby cancer cells hijack macrophages to promote tumor progression.

Authors

Sebastian P. Gnosa, Laia Puig Blasco, Krzysztof B. Piotrowski, Marie L. Freiberg, Simonas Savickas, Daniel H. Madsen, Ulrich auf dem Keller, Pauliina Kronqvist, Marie Kveiborg

×

Figure 2

ADAM17 is required for protumorigenic macrophage education.

Options: View larger image (or click on image) Download as PowerPoint
ADAM17 is required for protumorigenic macrophage education.
(A) Western ...
(A) Western blot of ADAM17 protein expression in WT and Adam17–/– (A17–/–) 4T1 and E0771 cell lines (representative of 3 repeats). β-Actin was used as control. (B) Left: Average tumor volume (mm3) ± standard deviation; Right: Survival curves of WT or Adam17–/– 4T1 (clone 2, n = 6 mice per group, top) and E0771 (clone 1, n = 22 mice per group, bottom) cells injected into the mammary fat pad of BALB/c or C57BL/6JRj mice, respectively. (C) Representative IHC stainings for CD163 in WT or Adam17–/– 4T1 and E0771 tumors. Scale bar: 200 μm. (D) Quantified CD163-positive cells/field from 3 fields/tumor in WT and ADAM17–/– 4T1 (n = 4 and 7, respectively) and E0771 (n = 10 and 4, respectively) tumors. (E) Experimental setup for qRT-PCR of bone marrow–derived macrophages (BMDM) upon coculture with cancer cells (used in F and G). (F) Relative CD163 (n = 4) and CD206 (n = 3) mRNA expression in macrophages cocultured with WT or 2 clones of Adam17–/– 4T1 cells, determined by qRT-PCR. β2 microglobulin (B2M) was used as control. (G) Relative CD163 (n = 3) and CD206 (n = 3) mRNA expression in macrophages cocultured with WT or 2 clones of Adam17–/– E0771 cells, determined by qRT-PCR. B2M was used as control. Mean and standard deviation indicated. Two-sided, unpaired Student’s t test (B, D, F, and G) and log-rank (B) tests were applied to test for significance; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts